Bortezomib to Treat Significant Complication of HSCT

NCT01929980 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Allogeneic Stem Cell Transplantation
Refractory Autoimmune Cytopenia(s)

Interventions

DRUG: Bortezomib

Sponsor

Children's Hospital Medical Center, Cincinnati